Mexifin ampoules 50mg/ml 5ml №10

Packaging

10 vials of 5 ml.

Mechanism of action

Mexifin belongs to the group of compounds of 3-hydroxypyridine and succinic acid and has antioxidant, antihypoxic, membrane stabilizing, nootropic, protective, anticonvulsant and anxiolytic effects. Mexifin acts as an inhibitor of free radicals, inhibits the processes of lipid peroxidation, increases the activity of the antioxidant enzyme system, restores the structure and function of membranes disturbed in various pathologies, has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, calcium-dependent cyclase, acetylchase deserase, the modulating effect) including benzodiazepine, GABA, acetylcholine; improves neurotransmitter transport, synaptic transmission and interrelation of brain structures. Increases the content in the brain dopamine. The mechanism of action of mexifin is due to its ability to enhance the compensatory activation of aerobic glycolysis.It reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, increasing the content of ATP and creatine phosphate; contributes to the preservation of the structural and functional organization of biomembranes. Mexifin improves brain metabolism and blood supply to the brain, corrects disorders in the regulatory and microcirculatory systems, suppressing constriction of arterioles and precapillaries; improves the rheological properties of blood, reducing platelet aggregation, stabilizing the membrane structure of blood cells (erythrocytes and platelets), preventing hemolysis; improves the immune system. Mexifin has an anti-atherogenic effect, causing regression of atherosclerotic changes in the arteries, reducing cholesterol and low-density lipoproteins, restoring lipid homeostasis. Mexifin increases the performance and resistance of the body to the effects of various extreme damaging factors in oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebral circulation disorders, physical and mental overload), alcohol intoxication and antipsychotics (neuroleptics).

Indications and usage

• acute disorders of cerebral circulation (as part of combination therapy);
• encephalopathy;
• vegetative vascular dystonia;
• mild cognitive impairment of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like conditions;
• relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• acute intoxication with antipsychotics.

Contraindications

Acute disorders of the liver and kidneys, increased individual sensitivity to the drug.
Children's age, pregnancy, breastfeeding - due to insufficient study of the drug in these categories of patients.

Dosage and administration

Mexifin prescribed intramuscularly or intravenously (jet or drip). Doses are selected individually. The duration of treatment and dosing regimen depends on the severity of the patient's condition and the effectiveness of treatment. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose to obtain a therapeutic effect. The maximum daily dose should not exceed 800 mg. When the infusion method of administration of the drug should be diluted in physiological sodium chloride solution. Jet Mexifin is injected slowly over 5-7 minutes; drip - at a rate of 60 drops per minute. Acute disorders of cerebral circulation: as part of combination therapy, intravenous drip at 200-300 mg in the first 2-4 days, then intramuscularly in a dose of 100 mg 3 times a day. Course duration - 10-14 days. Dyscirculatory encephalopathy (decompensation phase): intravenously in a stream or drip of 100 mg 2-3 times a day for 14 days, then intramuscularly at 100 mg per day for the next 14 days.Prevention of dyscirculatory encephalopathy: intramuscularly 100 mg 2 times a day for 10-14 days. Mild cognitive impairment in elderly patients and in anxiety disorders: intramuscularly at 100-300 mg per day for 14-30 days. Alcohol withdrawal syndrome: 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days. Acute neuroleptic intoxication: intravenous 50-300 mg per day for 7-14 days, depending on the severity of the condition. For neurotic disorders and vegetative-vascular dystonia, the drug is administered intramuscularly at a dose of 50-400 mg per day for 14 days.

Special notes

At the beginning of drug treatment, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration of attention and quickness of psychomotor reactions. Currently, a number of drugs with the same active ingredient ethyl methyl hydroxypyridine succinate are being produced, which should be considered when treating other diseases, in the treatment of which drugs with this substance can be used.

Drug Interactions

Potentiates the action of benzodiazepine anxiolytics, anticonvulsants and anti-parkinsonian drugs. The drug reduces the toxic effects of ethyl alcohol.

Overdosage

Overdose may cause drowsiness.

Storage conditions

Store in a dry, protected from light place inaccessible to children, at a temperature not exceeding 25 ° C.